【摘要】 目的 多药耐药性（MDR）是导致胆管癌化疗疗效不佳的主要原因，本研究通过检测胆管癌组织中MRP1和GSTπ的表达情况，探讨其耐药的临床意义。方法 收集2001年1至2007年12月收治并行手术切除的21例胆管癌标本，RTPCR方法检测标本中MRP1及GSTπ mRNA的表达。结果 MRP1和GSTπ mRNA在胆管癌组织中的表达阳性率分别76.2%和66.7%，显著高于对照组（P<0.05），上述指标与性别、年龄、病理分期、分化程度、淋巴结转移均无关（P>0.05）。结论 MRP1、GSTπ基因在未经过化疗的胆管癌组织中均有不同程度的高表达；胆管癌的原发性多药耐药可能与MRP1、GSTπ有关。
【关键词】 胆管癌 多药耐药相关蛋白 谷胱苷肽S转移酶π
Expression of multidrug resistancerelated genes MRP1 /GSTπ in carcinoma of cholangiocarcinoma and its significance
AN Jie，LIU Wei，GENG Jianying.
Department of Pathology，Bethune International Peace Hospital，Shijiazhuang 050082，China
【Abstract】 Objective Multidrug resistance is the main cause for the patients with cholangiocarcinoma for not responding to chemotherapy.To investigate the gene expression of multidrug resistancerelated protein 1（MRP1），glutathione Stransferaseπ（GSTπ）in cholangiocarcinoma in order to explore the clinical significance of multidrug resistance.Methods The expression of MRP1 and GSTπ in 21 cases of cholangiocarcinoma was measured by RTPCR method，while 8 cases of choledochitis served as the control group.Results The positive rates of MRP1，GSTπ mRNA in cholangiocarcinoma were 76.2%，66.7% respectively，which were significantly higher than those of control group（P<0.05）.Their expressions were not related to gender，age，staging，differentiation and lymph node metastasis（P>0.05）.Conclusion MRP1 and GSTπ are overexpressed in various degrees of cholangiocarcinoma without chemotherapy，which may be related to the primary multidrug resistance of the tumors.
【Key words】 cholangiocarcinoma；multidrug resistancerelated protein；glutathione S transferaseπ
多药耐药（multidrug resistance，MDR）是指当一种药物作用于肿瘤细胞使之产生耐受性后，该肿瘤对未接触过的、结构无关、机制不同的肿瘤药物也具有耐受性，产生交叉耐药。MDR是肿瘤细胞免受化疗药物攻击的最重要的细胞防御机制，也是造成化疗失败的主要原因。
[1] [2] [3] [4] 下一页
您现在的位置： 绿色健康网 >> 医学论文 >> 外科论文 >> 正文